Corresponding author: Neil Dawson. Correspondence through the editorial office: official@pagetree.org.
This conceptual analysis examines specification fidelity in immune-state and tumor evidence synthesis, using biomarker transformations, test suites, retrospective outcomes as the key comparison axes. The article develops a research agenda through critical comparison of published evidence. The primary literature contributes a bounded result: the review integrates cellular metabolism, nutrient/oxygen conditions, mitochondrial stress, and stromal metabolites as candidate mechanisms of persistence. A computational specification is a translation of a substantive question. Errors can occur in that translation even when every implementation step is correct. Build examples with known substantive answers, including boundary cases. Review diffs against a written endpoint dictionary and require approval for meaning-changing patches. The proposed comparison concerns biomarker transformations, test suites, retrospective outcomes; it would test whether the specific failure scenario is detected without erasing legitimate uncertainty. An integrated account should preserve the distinction between tissue contexts, clinical endpoints, and mechanistic claims and any stronger downstream decision.
Resetting Immunometabolic Set Points in Autoimmune Disease asks why autoimmune activity can persist or recur when conventional inflammation suppression does not durably change underlying cellular and tissue states (Xiao Yu et al. 2026e). Its methodological basis is a conceptual review proposing immunometabolic set points across immune and tissue compartments. The accessible evidence is specific: the review integrates cellular metabolism, nutrient/oxygen conditions, mitochondrial stress, and stromal metabolites as candidate mechanisms of persistence. The set-point framing asks whether durable remission requires changing a coupled metabolic state rather than only lowering an inflammatory marker. A unifying set point is a hypothesis, not an already validated clinical measurement or an established therapeutic protocol. The source supplies one part of the comparison involving biomarker transformations, test suites, retrospective outcomes. Its evidence should retain its original unit and scope; the present synthesis proposes a connection without claiming that the paper directly tested this integrated workflow.
The relevant question in DRAFT-RL: Multi-Agent Chain-of-Draft Reasoning for Reinforcement Learning-Enhanced LLMs is how multi-agent reinforcement learning can preserve structural diversity instead of repeatedly refining a single answer (Yuanhao Li et al. 2026b). Its methodological basis is agents generate several chain-of-draft trajectories, peer agents and a learned reward model select promising paths, and actor-critic updates feed those selections into later reasoning. The accessible evidence is specific: the paper evaluates code synthesis, symbolic mathematics, and knowledge-intensive question answering and reports gains in accuracy and convergence. It treats alternative drafts as an explicit exploration space rather than incidental sampling noise. Peer agreement can amplify correlated errors, and additional drafts increase inference and evaluation costs unless diversity is measured rather than assumed. This source enters the present review as a methodological comparison for evidence processing, not as evidence about disease biology, patient outcomes, or clinical efficacy. The transferable question is whether biomarker transformations remains correctly interpreted after a computational choice involving retrospective outcomes. Its task-specific validation cannot be borrowed to validate the clinical claim.
A useful boundary case is supplied by Evo-CuRL: Curriculum-Aware Reinforcement Learning over Code Lineage Graphs for Software Engineering Reasoning, concerned with how software-engineering reasoning can learn from the evolving ancestry of code states rather than isolated prompts and patches (Wei Tan et al. 2026). Its methodological basis is curriculum-aware reinforcement learning organized over code-lineage graphs, so training can expose increasingly difficult relationships among revisions and outcomes. The accessible evidence is specific: the conference record establishes a graph-and-curriculum formulation for software reasoning, with evaluation reported in the software-engineering setting. The lineage representation offers a natural way to retain failed branches, successful repairs, and prerequisite relations during learning. The value of a curriculum depends on graph construction, difficulty ordering, and whether benchmark lineages resemble real collaborative repositories. This source enters the present review as a methodological comparison for evidence processing, not as evidence about disease biology, patient outcomes, or clinical efficacy. The transferable question is whether biomarker transformations remains correctly interpreted after a computational choice involving retrospective outcomes. Its task-specific validation cannot be borrowed to validate the clinical claim.
A useful boundary case is supplied by Machine Learning–Based Prediction of Early Visual Field Nonrecovery after Endoscopic Surgery for Nonfunctioning Pituitary Adenomas with Clinically Accessible Biomarkers: A Dual-Center Study, concerned with whether accessible preoperative biomarkers can predict early visual-field nonrecovery after surgery for nonfunctioning pituitary adenomas (Sunjiang Liu et al. 2026). Its methodological basis is a retrospective dual-center design with LASSO selection, multivariable logistic modeling, and a nomogram; training comprised 268 patients and validation 100. The accessible evidence is specific: the study includes 368 patients, defines early improvement at postoperative day seven, and reports age, vertical tumor diameter, and fasting glucose as predictors; reported C-indices are approximately 0.747 and 0.753. It develops an accessible early-risk tool with geographically separate validation instead of relying solely on model fit in development data. Day-seven nonrecovery is not permanent visual loss; retrospective selection, limited validation events, and unmeasured care differences constrain interpretation. The contribution becomes relevant to specification fidelity when the workflow moves from biomarker transformations to retrospective outcomes. That transition is the review's proposed analytical focus, not a new result attributed to the source.
A useful boundary case is supplied by Immune Niches in Brain Tumors: Glial–Immune Cell Interactions and Spatial Microdomains, concerned with how spatial glial–immune interactions organize permissive and suppressive microdomains within brain tumors (Qian Guo et al. 2026). Its methodological basis is a review of astrocytes, microglia, oligodendrocyte-lineage cells, T cells, and myeloid cells across spatial tumor niches. The accessible evidence is specific: the abstract integrates cytokine, metabolic, hypoxic, and immunoediting mechanisms associated with immune suppression and exhaustion. It shifts attention from tumor-wide averages to interactions whose meaning depends on location and cell context. The review does not establish efficacy of a new intervention; co-location, state annotation, and functional interaction require different evidence. The contribution becomes relevant to specification fidelity when the workflow moves from biomarker transformations to retrospective outcomes. That transition is the review's proposed analytical focus, not a new result attributed to the source.
(Yidan Zhang et al. 2026) examines how splenic extramedullary granulopoiesis and neutrophil heterogeneity contribute to systemic cancer immunosuppression and resistance in Splenic Extramedullary Granulopoiesis and Neutrophil States in Cancer Immunity: Systemic Immunosuppression and Therapeutic Resistance. Its methodological basis is a review organized around stress-associated splenic blood-cell production and reprogrammed neutrophil states. The accessible evidence is specific: the official Cancer Bioscience recent-articles listing confirms the review's scope and emphasizes sustained stress and systemic reprogramming; no new patient cohort is inferred. The framing connects extra-tumoral immune production with local cancer resistance questions. The accessible summary cannot establish specific quantitative contributions, universal cell-state functions, or clinical effects of proposed targeting strategies. The source supplies one part of the comparison involving biomarker transformations, test suites, retrospective outcomes. Its evidence should retain its original unit and scope; the present synthesis proposes a connection without claiming that the paper directly tested this integrated workflow.
The relevant question in The Prediction of Extended Hospital Length of Stay in Patients after Endoscopic Endonasal Transsphenoidal Surgery for the Resection of Non-Functioning Pituitary Adenomas: A Dual-Center Retrospective Analysis is which retrospective clinical features predict extended hospital stay after endoscopic endonasal surgery for nonfunctioning pituitary adenomas (Bibo Gao et al. 2026). Its methodological basis is a dual-center retrospective prediction analysis with a modeled extended-stay outcome and separate validation. The accessible evidence is specific: the accessible record describes a nomogram and a 100-patient validation sample; specific predictor effects and thresholds are not assumed. It treats hospitalization burden as an explicitly predicted outcome that can inform care-process evaluation. Length of stay includes organizational and discharge factors; it is not an interchangeable measure of tumor biology, surgical quality, or long-term recovery. The source supplies one part of the comparison involving biomarker transformations, test suites, retrospective outcomes. Its evidence should retain its original unit and scope; the present synthesis proposes a connection without claiming that the paper directly tested this integrated workflow.
A useful boundary case is supplied by Towards Explainable RAG: Interpreting the Influence of Retrieved Passages on Generation, concerned with how generated answers can be interpreted through the influence of their retrieved passages (Yinghao. “Towards Explainable RAG: Interpreting the Influence of Retrieved Passages on Generation.” *2025 4th International Conference on Robotics Sang 2025). Its methodological basis is the supplied IEEE conference title frames passage-influence analysis for explainable retrieval-augmented generation; implementation particulars were unavailable. The accessible evidence is specific: the bibliographic item is located in the official IEEE record; no unverified attribution algorithm or benchmark result is inferred. It asks for traceability between particular retrieved evidence and generated statements instead of treating a bibliography as an explanation. Passage influence, citation support, causal explanation, and factual correctness are distinct properties; the accessible record cannot establish all of them. This source enters the present review as a methodological comparison for evidence processing, not as evidence about disease biology, patient outcomes, or clinical efficacy. The transferable question is whether biomarker transformations remains correctly interpreted after a computational choice involving retrospective outcomes. Its task-specific validation cannot be borrowed to validate the clinical claim.
The sources should be compared through the roles they play, not merged into a single performance claim. Resetting Immunometabolic Set Points in Autoimmune Disease addresses why autoimmune activity can persist or recur when conventional inflammation suppression does not durably change underlying cellular and tissue states (Xiao Yu et al. 2026e). By contrast, Towards Explainable RAG: Interpreting the Influence of Retrieved Passages on Generation addresses how generated answers can be interpreted through the influence of their retrieved passages (Yinghao. “Towards Explainable RAG: Interpreting the Influence of Retrieved Passages on Generation.” *2025 4th International Conference on Robotics Sang 2025). That difference matters for specification fidelity: the evidence concerning biomarker transformations is not automatically evidence concerning retrospective outcomes. A successful software operation, a plausible mechanistic account, and a validated outcome are different achievements. Their integration may improve traceability, but it cannot create an unmeasured link. A coherent review should identify where the sources complement one another and where their scopes remain incompatible. Here the proposed failure scenario is correct code producing an invalidly defined clinical endpoint. The analytical value of that scenario is that it can occur without requiring any cited paper to be wrong: an otherwise valid local finding can be misused at a later interface. Preventing that misuse requires evidence about the interface itself, not simply a larger collection of local results.
Biomarker transformations and retrospective outcomes occupy different positions in the evidence chain. Their relationship is the starting point for examining specification fidelity. Consider the possibility of correct code producing an invalidly defined clinical endpoint. This is a proposed stress scenario, not an observed event reported by the cited studies. Its purpose is to expose which evidence contract would be violated even if the final output looked plausible. For tissue contexts, clinical endpoints, and mechanistic claims, the relevant claim must identify its population or artifact class, its time window, and the action it is supposed to support. A failure at any of these levels may persist even after a local technical improvement. The analysis therefore treats published methods as bounded evidence and asks how their limitations interact with this particular decision. An operational analogy is useful only if it keeps those limitations visible.
A computational specification is a translation of a substantive question. Errors can occur in that translation even when every implementation step is correct. Repairing code requires preserving the intended denominator, units, exclusions, and endpoint logic. In this article, the relevant contrast is biomarker transformations, test suites, retrospective outcomes. The proposed counterexample of correct code producing an invalidly defined clinical endpoint puts that contrast under pressure. Build examples with known substantive answers, including boundary cases. Review diffs against a written endpoint dictionary and require approval for meaning-changing patches. A favorable finding would show that the intended interpretation of retrospective outcomes remains defensible when biomarker transformations is perturbed under the specified conditions. An unfavorable finding should narrow the claim rather than be discarded as an inconvenient case.
The strongest comparison would isolate the disputed transition in biomarker transformations, test suites, retrospective outcomes. The proposed counterexample, correct code producing an invalidly defined clinical endpoint, identifies what should not be accepted as equivalent evidence. The input record should retain enough information to decide which part of that scenario violates the intended contract. That includes the original source type, measurement or artifact status, and the reason the proposed interpretation exceeds its support. The evaluator would compare the system's response with a qualified judgment made without seeing that response. Disagreement should be classified rather than erased by rewriting the prompt. Repairing code requires preserving the intended denominator, units, exclusions, and endpoint logic. A useful negative result would show that the interface cannot preserve this distinction under realistic use; a useful positive result would demonstrate preservation on independent cases rather than merely on the example used to develop the rule. The primary source remains relevant through its particular contribution: The set-point framing asks whether durable remission requires changing a coupled metabolic state rather than only lowering an inflammatory marker. That contribution should be retained even if the integrated workflow fails. Conversely, successful integration would not remove the source's limitations or turn a proposed extension into an already observed result. This asymmetric interpretation protects both the literature and the user from an unjustified all-or-nothing verdict.
Replication and transparent workflows are prerequisites for reliable biomedical claims (National Academies 2019). Reproducing a calculation and independently replicating a finding are different achievements. Recoverable data and code allow one to inspect the first; independent observations and design choices inform the second. A review should avoid calling several reanalyses of one dataset separate replications. Clear reporting of analysis changes also makes a failed replication informative instead of allowing it to disappear as an implementation dispute. An implementation should expose this limitation to reviewers of tissue contexts, clinical endpoints, and mechanistic claims. The result and its evidence qualification should remain recoverable even when the interface condenses them into a short report.
FAIR principles support reusable cohorts, signals, and analysis metadata (Wilkinson et al. 2016). Reusable evidence needs more than a downloadable file. Identifiers, metadata, provenance, and meaningful access conditions help another researcher determine what an artifact contains and whether it can answer a new question. Reuse does not mean universal permission or universal scientific comparability. The information needed to judge those boundaries should travel with the artifact rather than remain in private workflow knowledge. This is methodological support for examining specification fidelity, not a claim that the source studied immune-state and tumor evidence synthesis. A separate application-specific test is required at the interface described in this review.
Causal inference requires a clearly specified intervention, time order, and exchangeability assumptions (Hernán and Robins 2020). A prediction can be accurate without identifying what an intervention would change. A useful causal analysis begins by defining the hypothetical comparison, eligibility, and time zero. Its assumptions concern the process generating exposure and observation, not merely the flexibility of a fitted model. In this review, causal vocabulary is appropriate only when that comparison can be specified and defended. For the comparison involving biomarker transformations, test suites, retrospective outcomes, the source supplies an analytical obligation. The review's proposed application remains a hypothesis, with the deliberately difficult scenario serving as a check on scope inflation.
Epidemiologic design makes confounding, selection, and measurement error part of interpretation (Rothman, Greenland, and Lash 2008). Confounding, selection, and measurement error are distinct problems and need not move an estimate in the same direction. An analysis should describe them before deciding which adjustment is adequate. A larger dataset can reduce random error while leaving systematic error almost untouched. Precision should therefore be interpreted alongside the quality of the design and the eligibility of its population. For the comparison involving biomarker transformations, test suites, retrospective outcomes, the source supplies an analytical obligation. The review's proposed application remains a hypothesis, with the deliberately difficult scenario serving as a check on scope inflation.
False-discovery control is central when many molecular features are screened (Benjamini and Hochberg 1995). Multiplicity arises from the family of questions actually searched. Controlling false discoveries within a named family does not automatically cover later tissue filters, alternative endpoints, or narrative choices. The proposed audit should retain exploratory branches so the family is visible. Independent confirmation then addresses a different question from whether a discovery threshold was correctly applied during screening. This is methodological support for examining specification fidelity, not a claim that the source studied immune-state and tumor evidence synthesis. A separate application-specific test is required at the interface described in this review.
Medical machine learning must fit data provenance, care pathways, and prospective evaluation (Rajkomar, Dean, and Kohane 2019). The clinical relevance of a model depends on how its output changes a care process. Development data can contain information that becomes available only after the intended decision. A review must identify that availability boundary before comparing algorithms. Prospective use also changes who is measured and who is treated, so evaluation of a frozen historical dataset cannot establish the entire future workflow. For the comparison involving biomarker transformations, test suites, retrospective outcomes, the source supplies an analytical obligation. The review's proposed application remains a hypothesis, with the deliberately difficult scenario serving as a check on scope inflation.
Responsible health AI connects prediction with workflow, monitoring, and patient impact (Wiens et al. 2019). The point at which a model reaches practice is not the end of evaluation. New populations, changing measurements, and feedback can alter failure modes. A responsible deployment needs a route for recognizing deterioration and a person authorized to respond. Monitoring should be linked to feasible corrective actions; an alert that cannot change the workflow provides accountability only in a very limited sense. An implementation should expose this limitation to reviewers of tissue contexts, clinical endpoints, and mechanistic claims. The result and its evidence qualification should remain recoverable even when the interface condenses them into a short report.
Policy distillation connects compression with sequential decision behavior (Rusu et al. 2015). Compressing a policy concerns sequential behavior rather than one isolated prediction. A small local mismatch can compound across actions, while a locally similar policy can explore differently. Evaluation should retain trajectories and consequential state transitions. The review treats policy transfer as a potential operational tool whose task-level contract still needs checking in the destination environment. For the comparison involving biomarker transformations, test suites, retrospective outcomes, the source supplies an analytical obligation. The review's proposed application remains a hypothesis, with the deliberately difficult scenario serving as a check on scope inflation.
BM25 remains an important lexical baseline for retrieval systems (Robertson and Zaragoza 2009). Lexical retrieval remains a useful baseline because it is explicit about matching the available terms. Semantic matching can add recall while confusing specialized senses that share broad context. A retrieval evaluation should include both exact-identifier and meaning-based cases. Comparing a new retriever with an appropriately tuned lexical baseline helps determine whether extra computation adds support rather than merely more plausible-looking passages. Within immune-state and tumor evidence synthesis, this distinction is relevant to specification fidelity. The proposed failure scenario is correct code producing an invalidly defined clinical endpoint; its evaluation must preserve the original source's methodological scope.
Retrieval-augmented generation makes external evidence part of the generation process (Lewis et al. 2020). Making documents available to a generator changes its information access but does not guarantee that a statement is supported. A useful analysis separates document selection from generation conditioned on those documents. Missing evidence, irrelevant context, and selective quotation create different failures. The proposed workflow should preserve retrieved passages and evaluate claim support independently of fluency or the mere presence of citations. The connection to repairing clinical feature pipelines without repairing evidence is a constraint on interpretation. It would be inappropriate to borrow the source's methodological authority as direct confirmation of the integrated domain claim.
Build examples with known substantive answers, including boundary cases. Review diffs against a written endpoint dictionary and require approval for meaning-changing patches. This would operationalize the concern with specification fidelity rather than assume it has been resolved by one successful output. These procedures are proposed, not completed. The case set would include the scenario of correct code producing an invalidly defined clinical endpoint, with its validity judged independently of the system's response. The relevant comparison axes are biomarker transformations, test suites, retrospective outcomes.
A contract-focused protocol would pair executable fixtures with written substantive requirements. Fixtures would cover units, exclusions, provenance, interruptions, and boundary cases. The evaluation would preserve the first interface at which a requirement fails and separate that failure from its downstream symptoms. A repaired or successfully replayed computation would not receive credit for scientific validity unless the requirement itself still expresses the intended question.
For the immune review, proposed mechanisms should be tested in their stated compartments and disease settings. Spatial association, state annotation, and intervention response would be judged separately. A useful result could expose a missing bridge in the integrated account. It would not need to confirm every part of the preferred narrative to improve scientific understanding.
Access limits are material for Towards Explainable RAG: Interpreting the Influence of Retrieved Passages on Generation. Where only bibliographic scope or a limited abstract is available, the discussion does not assign unverified datasets, algorithms, effect sizes, or clinical recommendations. This review is a bounded conceptual synthesis rather than a systematic review with an exhaustive search protocol. It cannot establish the effectiveness of the proposed integrated workflow. Its specific contribution is to articulate how specification fidelity changes the interpretation of biomarker transformations, test suites, retrospective outcomes. Technical sources support computational comparisons only; they do not validate biological mechanisms or patient benefit. Reviews and correspondence retain their publication roles and are not counted as new experiments. Proposed stress cases are illustrative, not observed failures attributed to the papers. Future work should therefore test the weakest inference described here, preserve contrary results, and disclose the cost of checking rather than treating additional automation as intrinsically beneficial.
The counterexample of correct code producing an invalidly defined clinical endpoint shows why local success and integrated validity must be evaluated separately. Build examples with known substantive answers, including boundary cases. Review diffs against a written endpoint dictionary and require approval for meaning-changing patches. The primary source remains bounded by its own design: A unifying set point is a hypothesis, not an already validated clinical measurement or an established therapeutic protocol. The cited studies provide useful but different forms of support. Their integration should increase traceability and expose missing links, leaving clinical, mechanistic, and operational claims at the strength justified by their own evidence.
1. Yu, Xiao, et al. “Resetting Immunometabolic Set Points in Autoimmune Disease.” Journal of Translational Autoimmunity, vol. 13, 2026, https://doi.org/10.1016/j.jtauto.2026.100391.
2. Li, Yuanhao, et al. “DRAFT-RL: Multi-Agent Chain-of-Draft Reasoning for Reinforcement Learning-Enhanced LLMs.” Proceedings of the AAAI Conference on Artificial Intelligence, vol. 40, no. 35, 2026, pp. 29530–37, https://doi.org/10.1609/aaai.v40i35.40195.
3. Tan, Wei, et al. “Evo-CuRL: Curriculum-Aware Reinforcement Learning over Code Lineage Graphs for Software Engineering Reasoning.” Proceedings of the 2026 International Conference on Multimedia Retrieval, ACM, 2026, pp. 1327–35, https://doi.org/10.1145/3805622.3810701.
4. Liu, Sunjiang, et al. “Machine Learning–Based Prediction of Early Visual Field Nonrecovery after Endoscopic Surgery for Nonfunctioning Pituitary Adenomas with Clinically Accessible Biomarkers: A Dual-Center Study.” International Journal of Clinical Practice, vol. 2026, no. 1, 2026, https://doi.org/10.1155/ijcp/2504255.
5. Guo, Qian, et al. “Immune Niches in Brain Tumors: Glial–Immune Cell Interactions and Spatial Microdomains.” Acta Neuropathologica Communications, vol. 14, 2026, https://doi.org/10.1186/s40478-026-02373-0.
6. Zhang, Yidan, et al. “Splenic Extramedullary Granulopoiesis and Neutrophil States in Cancer Immunity: Systemic Immunosuppression and Therapeutic Resistance.” Cancer Bioscience, 2026, https://doi.org/10.1016/j.cbs.2026.100009.
7. Gao, Bibo, et al. “The Prediction of Extended Hospital Length of Stay in Patients after Endoscopic Endonasal Transsphenoidal Surgery for the Resection of Non-Functioning Pituitary Adenomas: A Dual-Center Retrospective Analysis.” Cancers, vol. 18, no. 10, 2026, https://doi.org/10.3390/cancers18101582.
8. Sang, Yinghao. “Towards Explainable RAG: Interpreting the Influence of Retrieved Passages on Generation.” 2025 4th International Conference on Robotics, Artificial Intelligence and Intelligent Control (RAIIC), IEEE, 2025, pp. 397–400, https://doi.org/10.1109/raiic65850.2025.11170170.
9. National Academies of Sciences, Engineering, and Medicine. Reproducibility and Replicability in Science. National Academies Press, 2019.
10. Wilkinson, Mark D., et al. “The FAIR Guiding Principles for Scientific Data Management and Stewardship.” Scientific Data, vol. 3, 2016, article 160018.
11. Hernán, Miguel A., and James M. Robins. Causal Inference: What If. Chapman & Hall/CRC, 2020.
12. Rothman, Kenneth J., Sander Greenland, and Timothy L. Lash. Modern Epidemiology. 3rd ed., Lippincott Williams & Wilkins, 2008.
13. Benjamini, Yoav, and Yosef Hochberg. “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.” Journal of the Royal Statistical Society: Series B, vol. 57, no. 1, 1995, pp. 289–300.
14. Rajkomar, Alvin, Jeffrey Dean, and Isaac Kohane. “Machine Learning in Medicine.” New England Journal of Medicine, vol. 380, 2019, pp. 1347–58.
15. Wiens, Jenna, et al. “Do No Harm: A Roadmap for Responsible Machine Learning for Health Care.” Nature Medicine, vol. 25, 2019, pp. 1337–40.
16. Rusu, Andrei A., et al. “Policy Distillation.” arXiv, 2015, arXiv:1511.06295.
17. Robertson, Stephen, and Hugo Zaragoza. “The Probabilistic Relevance Framework: BM25 and Beyond.” Foundations and Trends in Information Retrieval, vol. 3, no. 4, 2009, pp. 333–89.
18. Lewis, Patrick, et al. “Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks.” Advances in Neural Information Processing Systems, vol. 33, 2020, pp. 9459–74.